CR20180003A - Métodos de modulación de moléculas de vigilancia de adn citosólicas - Google Patents

Métodos de modulación de moléculas de vigilancia de adn citosólicas

Info

Publication number
CR20180003A
CR20180003A CR20180003A CR20180003A CR20180003A CR 20180003 A CR20180003 A CR 20180003A CR 20180003 A CR20180003 A CR 20180003A CR 20180003 A CR20180003 A CR 20180003A CR 20180003 A CR20180003 A CR 20180003A
Authority
CR
Costa Rica
Prior art keywords
methods
modulation
molecules
cytosolic dna
dna surveillance
Prior art date
Application number
CR20180003A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Ilg
Jason Nickell
Christian Weiss
Alberth Abraham
Daniel Keil
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CR20180003A publication Critical patent/CR20180003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CR20180003A 2015-06-26 2016-06-23 Métodos de modulación de moléculas de vigilancia de adn citosólicas CR20180003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (1)

Publication Number Publication Date
CR20180003A true CR20180003A (es) 2018-03-20

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180003A CR20180003A (es) 2015-06-26 2016-06-23 Métodos de modulación de moléculas de vigilancia de adn citosólicas

Country Status (22)

Country Link
US (1) US20190233825A1 (enExample)
EP (1) EP3313376A2 (enExample)
JP (1) JP2018518511A (enExample)
KR (1) KR20180021874A (enExample)
CN (1) CN108472255A (enExample)
AR (1) AR105160A1 (enExample)
AU (1) AU2016282879A1 (enExample)
BR (1) BR112017028121A2 (enExample)
CA (1) CA2990526A1 (enExample)
CL (1) CL2017003373A1 (enExample)
CR (1) CR20180003A (enExample)
DO (1) DOP2017000313A (enExample)
HK (1) HK1256128A1 (enExample)
IL (1) IL256264A (enExample)
MX (1) MX2017017141A (enExample)
PE (1) PE20181208A1 (enExample)
PH (1) PH12017502413A1 (enExample)
RU (1) RU2018102915A (enExample)
SG (1) SG10201913395VA (enExample)
TW (1) TW201710509A (enExample)
UY (1) UY36756A (enExample)
WO (1) WO2016207314A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10933131B2 (en) 2016-07-26 2021-03-02 Bayer Animal Health Gmbh Increased fertility in bovine species
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
AU2001296354A1 (en) * 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失dnaワクチン
ES2543079T3 (es) * 2004-08-13 2015-08-14 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia antibiótica
CA2761736C (en) * 2009-05-14 2017-09-26 Bayer Animal Health Gmbh Enhanced immune response in avian species
SI2654785T1 (sl) * 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
JP5872684B2 (ja) * 2011-05-26 2016-03-01 インターベット インターナショナル ベー. フェー. 免疫刺激性オリゴデオキシヌクレオチド
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids

Also Published As

Publication number Publication date
RU2018102915A (ru) 2019-07-29
EP3313376A2 (en) 2018-05-02
JP2018518511A (ja) 2018-07-12
CL2017003373A1 (es) 2018-06-29
SG10201913395VA (en) 2020-03-30
DOP2017000313A (es) 2018-02-28
PE20181208A1 (es) 2018-07-23
PH12017502413A1 (en) 2018-06-25
CN108472255A (zh) 2018-08-31
US20190233825A1 (en) 2019-08-01
AR105160A1 (es) 2017-09-13
IL256264A (en) 2018-02-28
RU2018102915A3 (enExample) 2019-12-05
HK1256128A1 (zh) 2019-09-13
AU2016282879A1 (en) 2018-01-18
UY36756A (es) 2017-01-31
MX2017017141A (es) 2018-03-09
WO2016207314A3 (en) 2017-02-09
TW201710509A (zh) 2017-03-16
BR112017028121A2 (pt) 2018-09-04
WO2016207314A2 (en) 2016-12-29
CA2990526A1 (en) 2016-12-29
KR20180021874A (ko) 2018-03-05

Similar Documents

Publication Publication Date Title
MX376105B (es) Método para producir l-aminoacidos utilizando una bacteria alcalifílica.
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MD20160024A2 (ro) Modularea imunităţii tumorale
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
EP4015535C0 (en) GLYCO-ENGINEERING MODIFICATION OF SITE-SPECIFIC TARGETING MOIETIES
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX375524B (es) Anticuerpos anti-axl.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691374A1 (ru) Инсулин длительного действия и его применение
MX2021010460A (es) Metodo de tratamiento con tradipitant.
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
DOP2017000313A (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas
EP3602547C0 (en) TARGET SAMPLE GENERATION
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
EP3365321A4 (en) ZWITTERION OF SOLABEGRON AND ITS USES
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
DK3144383T3 (da) Mikroorganisme af Corynebacterium-slægten til fremstilling af L-lysin og fremgangsmåde til fremstilling af L-lysin under anvendelse af denne
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.